Liquidia (NASDAQ:LQDA) Price Target Raised to $52.00

Liquidia (NASDAQ:LQDA) had its price target lifted by Needham & Company LLC from $36.00 to $52.00 in a research note released on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of Liquidia in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Liquidia in a report on Monday, October 6th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a research report on Tuesday. Finally, Wells Fargo & Company began coverage on Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

Liquidia Trading Down 3.1%

Shares of Liquidia stock opened at $25.60 on Tuesday. The business has a fifty day simple moving average of $24.52 and a 200-day simple moving average of $19.70. Liquidia has a fifty-two week low of $9.71 and a fifty-two week high of $29.94. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -17.78 and a beta of 0.12. The company has a quick ratio of 2.41, a current ratio of 2.20 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, equities analysts forecast that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, Director Paul B. Manning sold 328,268 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $28.78, for a total transaction of $9,447,553.04. Following the transaction, the director directly owned 430,828 shares of the company’s stock, valued at approximately $12,399,229.84. The trade was a 43.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raman Singh sold 45,524 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $25.81, for a total value of $1,174,974.44. Following the sale, the director owned 31,255 shares of the company’s stock, valued at $806,691.55. The trade was a 59.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 849,141 shares of company stock valued at $23,584,920 in the last ninety days. Company insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Whitcomb & Hess Inc. lifted its position in Liquidia by 2.0% in the 3rd quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock worth $645,000 after buying an additional 558 shares in the last quarter. Ballentine Partners LLC increased its stake in shares of Liquidia by 10.2% in the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after acquiring an additional 1,119 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after acquiring an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its position in Liquidia by 6.4% during the first quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company’s stock valued at $373,000 after purchasing an additional 1,523 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).